Cargando…
Current guidelines for Helicobacter pylori treatment in East Asia 2022: Differences among China, Japan, and South Korea
Helicobacter pylori (H. pylori) infection is highly prevalent in East Asia. The overall seroprevalence rate of H. pylori infection is 44.2% in China, 37.6%-43.2% in Japan, and 51.0% in South Korea. H. pylori can cause peptic ulcer disease and gastric cancer. East Asian countries have high rates of g...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9294908/ https://www.ncbi.nlm.nih.gov/pubmed/35979311 http://dx.doi.org/10.12998/wjcc.v10.i19.6349 |
_version_ | 1784749948970991616 |
---|---|
author | Cho, Jun-Hyung Jin, So-Young |
author_facet | Cho, Jun-Hyung Jin, So-Young |
author_sort | Cho, Jun-Hyung |
collection | PubMed |
description | Helicobacter pylori (H. pylori) infection is highly prevalent in East Asia. The overall seroprevalence rate of H. pylori infection is 44.2% in China, 37.6%-43.2% in Japan, and 51.0% in South Korea. H. pylori can cause peptic ulcer disease and gastric cancer. East Asian countries have high rates of gastric cancer (age-standardized incidence rate: 20-30 per 100000). The Kyoto global consensus report emphasized that H. pylori gastritis should be considered the main cause for the development of gastric cancer. H. pylori treatment guidelines in China, Japan, and South Korea have recently been revised according to data from each of those countries. However, emerging antibiotic resistance is an important barrier to H. pylori eradication. The recommended H. pylori treatment regimens differ among those three East Asian countries. In this review, recent guidelines and up-to-date research on H. pylori treatment regimens from China, Japan, and South Korea are discussed. |
format | Online Article Text |
id | pubmed-9294908 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Baishideng Publishing Group Inc |
record_format | MEDLINE/PubMed |
spelling | pubmed-92949082022-08-16 Current guidelines for Helicobacter pylori treatment in East Asia 2022: Differences among China, Japan, and South Korea Cho, Jun-Hyung Jin, So-Young World J Clin Cases Minireviews Helicobacter pylori (H. pylori) infection is highly prevalent in East Asia. The overall seroprevalence rate of H. pylori infection is 44.2% in China, 37.6%-43.2% in Japan, and 51.0% in South Korea. H. pylori can cause peptic ulcer disease and gastric cancer. East Asian countries have high rates of gastric cancer (age-standardized incidence rate: 20-30 per 100000). The Kyoto global consensus report emphasized that H. pylori gastritis should be considered the main cause for the development of gastric cancer. H. pylori treatment guidelines in China, Japan, and South Korea have recently been revised according to data from each of those countries. However, emerging antibiotic resistance is an important barrier to H. pylori eradication. The recommended H. pylori treatment regimens differ among those three East Asian countries. In this review, recent guidelines and up-to-date research on H. pylori treatment regimens from China, Japan, and South Korea are discussed. Baishideng Publishing Group Inc 2022-07-06 2022-07-06 /pmc/articles/PMC9294908/ /pubmed/35979311 http://dx.doi.org/10.12998/wjcc.v10.i19.6349 Text en ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. |
spellingShingle | Minireviews Cho, Jun-Hyung Jin, So-Young Current guidelines for Helicobacter pylori treatment in East Asia 2022: Differences among China, Japan, and South Korea |
title | Current guidelines for Helicobacter pylori treatment in East Asia 2022: Differences among China, Japan, and South Korea |
title_full | Current guidelines for Helicobacter pylori treatment in East Asia 2022: Differences among China, Japan, and South Korea |
title_fullStr | Current guidelines for Helicobacter pylori treatment in East Asia 2022: Differences among China, Japan, and South Korea |
title_full_unstemmed | Current guidelines for Helicobacter pylori treatment in East Asia 2022: Differences among China, Japan, and South Korea |
title_short | Current guidelines for Helicobacter pylori treatment in East Asia 2022: Differences among China, Japan, and South Korea |
title_sort | current guidelines for helicobacter pylori treatment in east asia 2022: differences among china, japan, and south korea |
topic | Minireviews |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9294908/ https://www.ncbi.nlm.nih.gov/pubmed/35979311 http://dx.doi.org/10.12998/wjcc.v10.i19.6349 |
work_keys_str_mv | AT chojunhyung currentguidelinesforhelicobacterpyloritreatmentineastasia2022differencesamongchinajapanandsouthkorea AT jinsoyoung currentguidelinesforhelicobacterpyloritreatmentineastasia2022differencesamongchinajapanandsouthkorea |